Show less

Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.

Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

WHO Europe, commitment to enhancing Novel Meds Platform

WHO Europe, commitment to enhancing Novel Meds Platform

Natasha Azzopardi Muscat, 'Access to drugs must be affordable'

TRIESTE, 18 aprile 2024, 18:14

Redazione ANSA



"Every person, no matter their background or circumstances, should be able to access health services and medical products when needed, without experiencing financial hardship. Without affordable access to safe, quality-assured medical products, attaining good health and well-being and Universal Health Coverage becomes a distant dream". That is what Natasha Azzopardi Muscat, Director of Country Health Policies & Systems at the World Health Organization - Regional Office for Europe, said at the plenary discussion in Trieste on the meeting organized by CEI and WHO for the policy dialogue on "Building resilient pharmaceutical and health product systems." "The reality we face today is far from ideal - she added - We are seeing unprecedented levels of medicine stockouts and shortages due to disruptions in global supply chains.
    Many countries in the WHO European Region, including those here today, also deal with rising medical costs. These costs create a significant budgetary strain, often restricting patient access, increasing inequalities, and increasing out-of-pocket payments.
    Moreover, the ongoing cost-of-living crisis and rampant European inflation worsen matters". According to the director, "This policy dialogue in Trieste aims to serve as a powerful platform for us to address these challenges collectively.
    Trieste has always been the bridge between Western Europe, the Western Balkans, and the eastern part of the WHO European Region".
    "WHO/Europe - Azzopardi Muscat then underlined - recognizes this and is working with different stakeholders through the new Access to Novel Medicines Platform (NMP) - a neutral space for patients and representatives of industry, civil society, governments, and other stakeholders - to convene and discuss solutions together, focusing on transparency, solidarity, sustainability, and novel antimicrobials." The meeting in Trieste, "under the leadership and convening power of CEI," hosted by Italy, was fruitful "to share experiences and best practices between EU countries and candidate countries, including the Western Balkans." The director remarked, "Small countries face additional challenges in accessing these medicines and medical products as well as essential medicines due to their limited capacities and geographical limitations. WHO/Europe is working with them to find solutions to these complex issues."


Not to be missed


Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.